Business Wire

SmartStream Launch Eligibility API for Fast Access to Collateral Optimisation

4.5.2022 11:00:00 EEST | Business Wire | Press release

Share

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces a new solution, Eligibility API for Collateral Management Optimisation – a faster and more efficient way to get eligibility information contained within collateral agreements like CSA, GMRAs and OSLA’s, for both pre- and post-trade collateral optimisation.

With the impending UMR (Uncleared Margin Rules) phase 6 regulatory regime being implemented in September 2022, volumes of margin calls are expected to increase and there will be an inevitable squeeze on assets being pledged as collateral. This will result in a rise in demand for High Quality Liquid Assets (HQLA). In addition, with Interest rates forecast to rise – firms are looking at pre- and post-trade optimisation so as to efficiently use scarce HQLA and Cash. With this new solution SmartStream will provide firms with a way to publish eligible collateral for each legal agreement, which can then be consumed by their optimisation engines.

To achieve optimisation, a key component is the ability to access eligibility schedules from OTC and repo collateral systems quickly and easily. Seamlessly accessing what is eligible, and what haircuts apply to instruments across all agreements is fundamental. SmartStream’s new API allows fast and easy access to collateral, including the ability to upgrade seamlessly. In addition, the new solution allows the sourcing of eligibility information in real-time.

Jason Ang, Program Manager, Collateral Management, SmartStream, states: “We realise the UMR deadline is fast approaching, and we have made it easy for clients to deploy our new solution, and to manage future versions without the need for lengthy implementation projects. Furthermore, having a public API strategy, lowers the cost-of-ownership of the collateral solution. The demand for this new API is high and we are having conversations with the major banks on how they can use our eligibility to optimise their collateral in preparation for the future”.

SmartStream’s TLM Collateral Management is a comprehensive, automated data management solution that helps financial institutions lower the operational risks associated with collateral management programmes. It offers a variety of functions, with coverage for cleared and non-cleared, OTC derivatives margining, repo margining and securities lending margining.

End

Visit: www.smartstream-stp.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:

Shamira Alidina, Media Relations Director, Dina Communications
Tel: +44 (0) 7801 590718
Email: shamira@dinacomms.com

Nathan Gee, Marketing Director, SmartStream
Tel: +44 (0) 20 7898 0630
Email: nathan.gee@smartstream-stp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Collaborates with Chainguard to Strengthen Software Supply Chain Security through BlueVerse™ RightLogic6.8.2026 14:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic collaboration with Chainguard, the trusted source for open source, to strengthen software supply chain security through BlueVerse™ RightLogic, LTM's cybersecurity assessment and risk assurance framework. The collaboration enables organizations to strengthen security while maintaining the speed and agility required for AI-enabled software development. With BlueVerse RightLogic, LTM combines AI-powered cyber risk assessment with a growing ecosystem of technology partners to help enterprises identify, assess, and remediate cyber exposure while accelerating AI adoption. Chainguard strengthens the BlueVerse RightLogic ecosystem by helping enterprises secure open-source components from the outset, complementing LTM's cybersecurity services to close the gap between AI-speed discovery and enterprise-speed remediation. As AI adoption accelerates, complex software supply chains and growing relian

teamLab Borderless in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries6.8.2026 14:07:00 EEST | Press release

teamLab Borderless: MORI Building DIGITAL ART MUSEUM (teamLab Borderless) in Tokyo has welcomed over 4 Million visitors as of July 31, 2026, approximately 2 years and 5 months since its opening.*1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806672709/en/ teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries These visitors arrived from more than 185 countries and regions. International visitors account for approximately 70% of the total number. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom and Germany. Among those who visited Japan between February 2024 and June 2026, approximately 1 in every 12 travelers from the United States, and 1 in every 9 travelers from Australia visited teamLab Borderless.*2 teamLab Borderless was selected by the U.S. based int

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 20266.8.2026 14:00:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under eva

Purina Named as First Publicly Announced NIQ ConnectAI Charter Client6.8.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named Purina as the first publicly announced client in its ConnectAI Charter Program. The announcement follows NIQ’s launch of the program with five global organizations across personal care, pet care, beauty and beverages, with additional client announcements and case studies expected as engagements advance. Through ConnectAI, NIQ forward-deployed engineers and data scientists are working within Purina’s technology environment to explore how NIQ consumer and market intelligence can support everyday AI-enabled workstreams and help teams access relevant insights more efficiently. "Understanding the needs of pet owners requires a clear view of how consumer behaviors, shopping habits, and category trends are evolving,” said Brian Donovan, Strategy and Insights, Purina. “Purina is working with NIQ to explore how its trusted intelligence can be incorporated into Purina’s everyday, AI-enabled workstreams, helping our team

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye